Skip to content
AnalystLens

Thermo Fisher Scientific 8-K Report, Financial Results (Jul 24, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed July 24, 2024
Period End
July 24, 2024
Security
TMO
In the record · 2016–202610-K1110-Q338-K153

TMO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 153 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Aug ’18Aug ’18
  2. Leadership change8-K · Nov ’20Nov ’20
  3. Material agreement8-K · Nov ’22Nov ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed July 24, 2024. Cited figures are marked; the original filing is the authoritative source.

Thermo Fisher Scientific reported second quarter 2024 results for the quarter ended June 29, 2024.

Revenue was $10.54 billiona, down 1% from $10.69 billion a year earlier, with organic revenue down 1% and Core organic revenue growth flat. Profitability was the bright spot on a GAAP basis: diluted EPS rose 15% to $4.04, and GAAP operating margin expanded to 17.3% from 14.8%, helped by lower restructuring charges and lower amortization of acquisition intangibles. Adjusted EPS rose 4% to $5.37, while adjusted operating income slipped to $2.35 billion from $2.37 billion, with adjusted operating margin edging up to 22.3% from 22.2%.

Cash generation was strong. Free cash flow for the quarter was $1.67 billionb, up from $1.26 billion, and year-to-date free cash flow reached $2.58 billion versus $1.54 billion. Management raised full-year 2024 guidance modestly: revenue to $42.4–43.3 billion (low end raised from $42.3 billion) and adjusted EPS to $21.29–22.07 (from $21.14–22.02).

Management also noted the completed acquisition of Olink shortly after quarter end. The results point to flat underlying demand offset by margin discipline and cost control, with the guidance change being incremental rather than a meaningful shift in outlook. Investors should note that the Life Sciences Solutions segment was the main driver of margin improvement, with segment margin rising to 36.7%c, while Laboratory Products and Biopharma Services margin fell to 12.9% from 14.1%.

Balance sheet activity included $3.0 billiond of share repurchases in the first half and $1.2 billion of new debt issuance, while cash declined and short-term investments rose. Because the filing is a Form 8-K furnishing the earnings release, the information is not deemed filed under Section 18 of the Exchange Act.

02—Key points

Key Highlights

  1. Q2 2024 revenue of $10.54B declined 1% year over year; organic revenue was down 1% and Core organic revenue growth was flat, reflecting weak underlying demand.
  2. GAAP diluted EPS rose 15% to $4.04, and GAAP operating margin expanded to 17.3% from 14.8%, aided by lower restructuring and amortization charges.
  3. Adjusted EPS rose 4% to $5.37, while adjusted operating income fell slightly to $2.35B from $2.37B; adjusted operating margin improved modestly to 22.3%.
  4. Free cash flow was $1.67B in Q2 (up from $1.26B) and $2.58B year to date (up from $1.54B), a strong cash generation result.
  5. Full-year 2024 guidance was raised: revenue to $42.4–43.3B (low end up $0.1B) and adjusted EPS to $21.29–22.07 (from $21.14–22.02).
  6. Life Sciences Solutions segment margin rose to 36.7% from 33.2%, while Laboratory Products and Biopharma Services margin declined to 12.9% from 14.1%.
  7. Olink acquisition closed shortly after quarter end, extending the company's proteomics capabilities.

03—Questions

Frequently Asked Questions

  1. Did Thermo Fisher's revenue grow in Q2 2024?

    No. Revenue declined 1% to $10.54 billion from $10.69 billion. Organic revenue fell 1%, and Core organic revenue growth (excluding COVID-19 testing and acquisitions/currency effects) was flat.

  2. Why did GAAP EPS rise 15% when revenue fell?

    GAAP operating income grew to $1.82 billion from $1.58 billion, driven by lower restructuring charges ($77 million vs. $183 million), lower amortization of acquisition intangibles ($513 million vs. $585 million), and lower cost of revenues as a percentage of sales. Share count also declined slightly, from 388 million to 383 million diluted shares.

  3. Did Thermo Fisher change its 2024 outlook?

    Yes, modestly. Revenue guidance was raised to $42.4–43.3 billion from $42.3–43.3 billion, and adjusted EPS guidance was raised to $21.29–22.07 from $21.14–22.02. The changes are small and mainly lift the low end of the ranges.

  4. How strong is the company's cash generation?

    Strong. Operating cash flow for the first half was $3.21 billion, and free cash flow was $2.58 billion, up from $1.54 billion a year earlier. The company also returned $3.0 billion to shareholders through share repurchases in the first half.

  5. What does the Olink acquisition mean for investors?

    The company closed its acquisition of Olink, a provider of next-generation proteomic solutions, shortly after the quarter ended. The deal expands Thermo Fisher's position in protein research and precision medicine. The filing does not disclose the purchase price or expected financial contribution in this release.

04—Continue

← View all 8-K filings